

Oncology Today with Dr Neil Love: Newly Approved Agents in the Management of Urothelial Bladder Carcinoma (Interview Audio)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Of the toxicities listed below, which are more commonly experienced by patients who are receiving enfortumab vedotin?**
 - Hypertension and myocardial ischemia
 - Thrombocytopenia, pneumonitis and diarrhea
 - Rash, ocular toxicities and peripheral neuropathy**
- 2. Which of the following drug types best describes the mechanism of action of enfortumab vedotin?**
 - Monoclonal antibody
 - Antibody-drug conjugate targeting nectin-4**
 - Small molecule tyrosine kinase inhibitor
- 3. Recommendations for mitigating the hyperphosphatemia associated with erdafitinib include which of the following options?**
 - Withhold drug
 - Reduce dose
 - Add an oral phosphate binder
 - All of the above**
 - Both a and c
- 4. Which drug type best describes the mechanism of action of sacituzumab govitecan?**
 - Anti-PD-1 monoclonal antibody
 - Anti-PD-L1 monoclonal antibody
 - Antibody-drug conjugate targeting Trop-2**